This strategic alliance will be offered to current and prospective clients to support the development of regenerative medicines, including CAR T-cell and gene therapies.
"The promise of regenerative medicine requires an innovative look at the complete product life cycle from market access planning through efficient distribution and best-in-class patient support. With Cryoport, we add real time logistics solutions with its standard setting Chain of Compliance, which includes "chain of condition", "chain of custody" and "chain of identity", to our global distribution and patient service capabilities," said Jim Lang, EVERSANA’s chief executive officer. "Their temperature-controlled logistics solutions are currently used by almost all of the leading biopharma companies. Our alliance will drive synergistic revenue growth for both of our companies and provide synergistic value to our clients."
Jerrell Shelton, Cryoport’s chief executive officer added, "Through our alliance, Cryoport will provide EVERSANA and its clients with our full suite of logistics solutions under our 'powered by cryoport' marketing model. EVERSANA is building a powerhouse, currently serving over 500 life sciences companies, over 100 therapeutics areas, including cell and gene therapies, across 80 countries. Our alliance will enable us to broaden the distribution of our solutions and more broadly answer demand from regenerative medicine companies for temperature-controlled for supply chain services. We are proud to partner with EVERSANA to offer an advanced integrated supply chain solution to our collective base of clients.”